Mast Cell, Anaphylaxis and Other Hypersensitivity
15 cases on idiopathic anaphylaxis prophylaxis, systemic mastocytosis and cytoreductive therapy, mast cell activation syndrome, hereditary alpha-tryptasemia and venom immunotherapy duration, food- and non-food-dependent exercise-induced anaphylaxis, latex-fruit cross-reactivity, biologic-induced anaphylaxis and rechallenge decisions, beta-blocker-refractory anaphylaxis management, Kounis syndrome, anaphylaxis during supervised food challenges, REMA-guided bone marrow biopsy thresholds, epinephrine autoinjector needle-length adequacy, omalizumab as steroid-sparing therapy, and monoclonal mast cell activation syndrome — choose a case below to open its full multi-voice debate.
Four unexplained anaphylactic episodes and a workup below the frequency threshold for standing prophylaxis — when to treat versus keep testing.
Indolent systemic mastocytosis outgrowing its antihistamine ceiling — when a low-dose KIT inhibitor trial actually applies, and what re-staging changes first.
A patient requesting mast-cell-directed therapy before the 2019 consensus mediator criteria have actually been met — treating and testing without making one wait on the other.
A beekeeper's genetic tryptase finding is real but unstudied as a venom-immunotherapy duration variable — standard course now, or plan for lifelong coverage today.
A competitive athlete's wheat-dependent exercise anaphylaxis and the real limits of a population-derived pre-exercise avoidance window at elite training intensity.
Three unexplained anaphylactic episodes on long training runs — why the real safety net here is behavioral, not pharmacologic, even while a drug trial proceeds.
Latex-fruit cross-reactivity spans a classic, well-established group and a much thinner-evidence extended list — why they don't call for the same avoidance decision.
Anaphylaxis after 26 well-tolerated omalizumab doses — why switching, not rechallenge, was chosen, and how the replacement regimen was built to close the gap.
A wasp sting, a chronic beta-blocker, and a blood pressure that won't respond to standard epinephrine dosing — the pharmacologic logic for adding glucagon rather than waiting.
Contrast anaphylaxis and a new ST-elevation mid-resuscitation — why dose and route, not a give-or-withhold choice, is what actually governs epinephrine's coronary risk here.
An objective, multi-organ reaction during a monitored baked-milk challenge — why a fully staffed, equipped room changes the epinephrine-timing calculus, and why a positive result at dose four isn't a failed challenge.
A urticaria-free anaphylactic syncope and a tryptase below the classic biopsy threshold — why a validated risk score, and a cheap genetic test to clear its main confound, changes the answer.
A technically correct autoinjector use that only partially worked — what the published skin-to-muscle distance data in obesity actually explains, and what it doesn't.
Visible steroid toxicity after 8 months managing frequent idiopathic anaphylaxis — weighing a thinner-evidence biologic against continuing a well-established but costly protocol.
A KIT D816V finding that falls just short of systemic mastocytosis — why MMAS still changes how long venom immunotherapy should run, even without a full diagnosis.